Last reviewed · How we verify
Stelara PFS
At a glance
| Generic name | Stelara PFS |
|---|---|
| Also known as | Ustekinumab |
| Sponsor | Alvotech Swiss AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS). (PHASE1)
- Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stelara PFS CI brief — competitive landscape report
- Stelara PFS updates RSS · CI watch RSS
- Alvotech Swiss AG portfolio CI